Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054803 | 0.93 | HTR5A (0.34) | HTR5AAGTR1BRS3 | |
| SCHEMBL3042077 | 0.84 | QPCT (0.34) | HTR5AAGTR1BRS3 | |
| Trifluoroacetic Acid SCHEMBL3046355 | 0.78 | HDAC6 (0.40) | HTR5A | |
| SCHEMBL3050687 | 0.77 | HTR5A (0.34) | HTR5AAGTR1BRS3 | |
| SCHEMBL3829848 | 0.77 | HSD11B1 (0.33) | PKMPTGES | |
| SCHEMBL3048447 | 0.77 | CNR2 (0.36) | HTR5AAGTR1CSF1RBRS3 | |
| Trifluoroacetic Acid SCHEMBL3054801 | 0.77 | VSIR (0.42) | HTR5A | |
| SCHEMBL3044737 | 0.76 | HTR5A (0.33) | HTR5AAGTR1FFAR4BRS3 | |
| SCHEMBL3046204 | 0.76 | HTR5A (0.36) | HTR5APTGESBRS3 | |
| SCHEMBL3048938 | 0.74 | MELK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | PKM 3535/4885HTR5A 190/4885AGTR1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.